Dalia M.
295 posts

Dalia M.
@DCCancerDoc
Cancer Doctor in Washington, D.C. Sherlock loving Hematologist Oncologist. Data science and informatics lover. Reality 🧜♀️ 🎹 🎤⚽️

@DCCancerDoc chaired the session for Areas of Unmet Needs to be considered for future drug development in Oncology #ET24. Stay Tuned for next years’ exciting topics! @InovaCME @InovaSchar @InovaHealth



















Dr. Faysal Haroun @Cancer_talks discusses the different 1L chemo-free IO options in NSCLC. Despite crossover, clear OS benefit makes 1L IO the clear SOC but different delivery options. Dual checkpoint blockade with impressive long term OS but in need of biomarkers. #DCLung22

Antibody drug conjugates increasingly relevant for NSCLC as discussed by Dr. @benlevylungdoc at #DCLung22 with highlights including trastuzumab deruxtecan (T-DXd) in #HER2 mutant NSCLC (dose is 5.4 mg/kg) and patritumab deruxtecan (HER3-DXd) in #EGFR mutant NSCLC. #LCSM

Update on #ROS1 NSCLC by Dr. @JessicaJLinMD at #DCLung22 including latest data on repotrectinib from #ENA2022. Promising activity with novel agents including against ROS1 G2032R especially NVL-520 with compelling (early) efficacy and safety data, first presented a few days ago!













